John Hancock's trial run will offer reimbursement to just under 10,000 customers who opt to take Illumina-owned Grail's early detection blood test that screens for 50 different types of cancer.
The tests screen for cancers that often go undetected, but they are expensive and some experts worry they could lead to unnecessary treatments without saving patients’ lives.
Several drug companies are pushing for the blood test as part of regular health screening to find cancerous growths. Experts are not sure whether the tests could improve Americans’ health or help cut the cancer death rate.